Medication Guide App

Arpida Presents a Large Body of Preclinical and Clinical Data at Scientific Conferences

REINACH and BASEL, Switzerland, August 07, 2007 /PRNewswire-FirstCall/ -- Arpida Ltd. announced today that it will be presenting a large volume of data on iclaprim at the upcoming Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on 17 - 20 September 2007 in Chicago and at the annual meeting of the Infectious Diseases Society of America (IDSA) on 4 -7 October in San Diego. Furthermore, data on AR-709 and AR-2474 will be presented at ICAAC.

ICAAC and IDSA are major scientific conferences where thousands of scientists and physicians gather to discuss the latest developments in their respective areas. A total of 37 posters have been accepted at these conferences. Additional information can be found on the conference websites.

    The following 19 abstracts on iclaprim have been accepted by ICAAC.


    Nr.  Author      Title

    630  Koeth       The Effect of Testing Parameter Variations on the In

                     Vitro Activity of Iclaprim against Staphylococcus aureus


    736  Mason       In Vitro Activity of Iclaprim against Community-Acquired

                     and Nosocomial Clinical Isolates of Staphylococcus

                     aureus


    737  Cevenini    In Vitro Activity of Iclaprim and Comparators against

                     Chlamydia trachomatis


    1073 Aranza      Iclaprim (ICL) Defined Quality Control (QC) Limits for

                     MIC and Disk Diffusion (DD) Susceptibility Testing

                     According to CLSI M23-A2 Procedures


    1342 Brandt      Pharmacokinetics and Bioavailability of Iclaprim Oral

                     and Intravenous Formulations in Humans


    1487 Brandt      Absorption, Pharmacokinetics, Metabolism and Excretion

                     of Iclaprim in Healthy Humans


    1491 Brandt      Pharmacokinetics and Metabolism of [14C]Iclaprim in the

                     Marmoset


    1499 Brandt      Interactions of Iclaprim with Human Cytochrome P450

                     Enzymes


    1502 Brandt      Tolerability and Pharmacokinetics of Single and Repeat

                     Ascending Doses of Iclaprim in Healthy Adults


    1545 Murphy      Comparative Efficacy of Iclaprim (ICL) against Wild-Type

                     and Thymidine Kinase-Deficient S. aureus in a Mouse

                     Protection Model


    1574 Jones       Bactericidal Activity and Post-Antibiotic Effect of

                     Iclaprim (ICL) against Staphylococcus aureus (SA)


    1667 Brown       In Vitro Activity of Iclaprim against Clinical Isolates

                     of Legionella pneumophila


    1923 Engelhardt  Comparative Evaluation of Iclaprim (ICL) MIC Testing

                     with Etest and CLSI Reference Methods


    1971 Sader       In Vitro Activity of Iclaprim and Comparison Agents

                     Tested against Neisseria gonorrhoeae Including Growth

                     Stimulating Effects


    1985 Sader       Antimicrobial Activity of a Novel Dihydrofolate

                     Reductase, Iclaprim, Tested against Clinical Strains of

                     Enterobacteriaceae (ENT): Results from the International

                     Study of Iclaprim Susceptibility (ISIS)


    1991 Hadvary     Microbiological Efficacy of Iclaprim against

                     Staphylococcus aureus in Complicated Skin and Skin

                     Structure Infection (cSSSI): Preliminary Results of

                     ASSIST-1


    2000 Sader       Comparative Evaluation of Iclaprim Potency and

                     Bactericidal Activity Tested against Enterococci:

                     Results from the International Study of Iclaprim

                     Susceptibility (ISIS)


    2016 Sader       In Vitro Activity of Iclaprim, a Novel

                     Diaminopyrimidine,Tested against beta-Haemolytic

                     Streptococci from the U.S.and Europe: Results from the

                     International Study of Iclaprim Susceptibility (ISIS).


    2198 Sader       Antimicrobial Activity of Iclaprim Tested against Recent

                     S. aureus Clinical Isolates: Results from the

                     International Study of Iclaprim Susceptility (ISIS)


    The following five abstracts on iclaprim have been accepted by IDSA.


    Nr.  Author      Title

    448  Hadvary     Pharmacokinetics of Iclaprim in Subjects with Varying

                     Degree of Hepatic or Renal Insufficiency or Obesity


    432  Hadvary     Evaluation of the Effect of Iclaprim on the QT Interval

                     in Healthy Volunteers


    1104 Leighton    Safety of Iclaprim in Complicated Skin and Skin

                     Structure Infections: ASSIST-1 Results


    1083 Hadvary     Effect of Iclaprim on the QT Interval Based on Results

                     of ASSIST-1


    1079 Stevens     Efficacy of Iclaprim in Complicated Skin and Skin

                     Structure Infections: Preliminary Results of ASSIST-1


    The following five abstracts on AR-709 have been accepted by ICAAC.


    Nr.  Author      Title

    735  Hawser      Post-Antibiotic Effects of AR-709 against Pneumococci


    1203 Ressner     Determination of the Activity of the Diaminopyrimidine

                     AR-709 against Recent Multidrug-Resistant North American

                     Isolates of Invasive Streptococcus pneumoniae


    1543 McKenney    Efficacy of AR-709 in Pneumococcal Murine Pneumonia


    1914 Honeybourne Concentrations of AR-709 in Plasma and Key Compartments

                     of the Lungs after Microdosing


    1929 Lappin      Plasma Pharmacokinetics of AR-709 Administered to Male

                     Healthy Volunteers as Microdoses by the Intravenous and

                     Oral Route


    The following eight abstracts on AR-2474 have been accepted by ICAAC.


    Nr.  Author      Title

    417  Pankuch     Comparative Activity of Three 1,3-Diphenyl Ureas against

                     S. pyogenes Compared to Other Agents


    418  Pankuch     Antipneumococcal Activities of Three 1,3-Diphenyl Ureas

                     Compared to Other Agents


    419  Pankuch     Antistaphylococcal Activity of Three 1,3-Diphenyl Ureas

                     Compared with Other Drugs


    430  Lociuro     Spectrum of Activity of Three Novel 1,3-Diphenyl Ureas

                     AR-2474, AR-2475 and AR-3752


    432  Hawser      Bactericidal Activity, Post Antibiotic Effect (PAE), and

                     Synergy Studies with AR-2474 A Novel 1,3-diphenyl Urea

                     Topical Antibiotic


    433  Zampaloni   In Vitro Mutation Studies with Novel 1,3-Diphenyl Urea

                     AR-2474


    498  Rouse       Initial Efficacy Studies of AR-2474, a Novel 1,3-

                     Diphenyl Urea, in MRSA Skin Infection and Nasal

                     Decolonization Mouse Models


    524  Weiss       Activity of the Novel 1,3-Diphenyl Urea AR-2474 against

                     Community-Acquired and Nosocomial Staphylococcus aureus

                     Isolates


About Arpida Ltd.

Arpida is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance.

Arpida's leading product candidate is intravenous iclaprim, a broad-spectrum antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In July 2007, Arpida reported the completion of the Phase III programme in complicated skin and skin structure infections. An NDA filing is expected to take place in the second half of 2007.

In June 2007, Arpida announced that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed three Phase I trials: an ADME study (absorption, distribution, metabolism and excretion) with radiolabelled compound, a Phase I bioavailability trial with a solution and one with a capsule formulation. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Arpida contacts:


    Dr Khalid Islam

    President and CEO

    Tel: +41-61-417-96-60


    Harry Welten

    MBA, CFO and Senior Vice President

    Tel: +41-61-417-96-65


    Paul Verbraeken

    Head of Corporate Communications

    Tel: +41-61-417-96-83



CONTACT: Arpida contacts: Dr Khalid Islam, President and CEO, Tel:+41-61-417-96-60; Harry Welten, MBA, CFO and Senior Vice President, Tel:+41-61-417-96-65; Paul Verbraeken, Head of Corporate Communications, Tel:+41-61-417-96-83

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: August 2007

View comments

Hide
(web2)